Latest Biomaterials News

Page 2 of 3
Nanollose Limited reported a $1.43 million loss for FY2025 while progressing pilot production of innovative biomaterials and strengthening its balance sheet with a $2.1 million capital raise. The company appointed a new CEO to drive commercialisation efforts in FY2026.
Maxwell Dee
Maxwell Dee
29 Aug 2025
Tetratherix Limited advances its Tetramatrix biomaterial platform with a robust IP portfolio, scalable manufacturing, and strategic partnerships aimed at commercialising across multiple clinical franchises.
Ada Torres
Ada Torres
28 Aug 2025
Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.
Ada Torres
Ada Torres
28 Aug 2025
Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.
Ada Torres
Ada Torres
28 Aug 2025
ReNerve Limited has achieved a key milestone with its first sale and clinical use of a deep dermal tissue product in the US, broadening its surgical applications beyond nerve repair. This move complements its existing nerve repair portfolio and sets the stage for further product launches later this year.
Ada Torres
Ada Torres
18 Aug 2025
Tetratherix has landed a $3.3 million Australian Government grant to co-fund a $7.4 million project expanding its synthetic polymer production and supporting its US market entry in 2026.
Ada Torres
Ada Torres
14 Aug 2025
Nanollose Limited has completed a successful pilot manufacturing run blending its Nullarbor-20 fibre with wool, raised $1.05 million through an entitlement issue, and appointed Andrew Moullin as CEO to drive its commercialisation strategy.
Maxwell Dee
Maxwell Dee
31 July 2025
Nanollose Limited has appointed Andrew Moullin as its new CEO and Managing Director, aiming to leverage his extensive commercial expertise to fast-track the company’s microbial cellulose technology towards market readiness.
Maxwell Dee
Maxwell Dee
30 May 2025
ReNerve Limited has gained marketing approval for its NervAlign® Nerve Cuff™ in Bahrain, marking its first regulatory success in the Middle East and opening access to a rapidly expanding regional market.
Ada Torres
Ada Torres
28 May 2025
Nanollose has successfully placed the $1.05 million shortfall from its recent entitlement offer, bolstering its capital to advance production and commercialisation of its innovative biomaterials.
Maxwell Dee
Maxwell Dee
20 May 2025
Nanollose Limited has achieved a significant milestone by blending its Nullarbor-20™ sustainable fibre with Australian merino wool to produce pilot blankets, while also completing a $672,000 placement to fund ongoing commercialisation efforts.
Maxwell Dee
Maxwell Dee
30 Apr 2025
ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.
Ada Torres
Ada Torres
29 Apr 2025